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Background: Corticosteroids and calcineurin inhibitors (CNIs) are included in renal transplantation
immunosuppressive protocols around the world. Well-known side effects are associated with the use of these drugs,
including new onset of diabetes after transplantation (NODAT). Long-term patient survival rates are lower among
patients with NODAT. The optimal immunosuppressive protocol would therefore include not using corticosteroids
and minimization of CNI use.
Methods/Design: This is a prospective, multi-centre, controlled, randomized, parallel group, open-label study
involving kidney transplant patients. The study compares a steroid-free immunosuppressive protocol (study arm A),
which is based on low-dose tacrolimus and mycophenolate mofetil (MMF) maintenance therapy together with
antithymocyte globulin (ATG) induction, with the conventional immunosuppressive protocol (study arm B), being
based on low-dose tacrolimus, MMF and steroids together with interleukin-2 receptor (IL2-R) induction. The study is
designed to include most normal-risk patients. It will exclude patients seen as at a high risk of rejection. The primary
objective of the study is to assess the cumulative incidence of NODAT in the two study arms 12 months after
transplantation using the American Diabetes Association type 2 diabetes diagnostic criteria. The composite measure
of freedom from acute rejection, graft survival and patient survival will be evaluated. Renal function and chronic
changes in the transplanted kidney will be assessed.
Discussion: If this study confirms conceptual expectations, namely decreased incidence of NODAT, the steroid-free
study protocol could be used with all patients. The regimen could be especially beneficial for patients at a high risk
of diabetes mellitus.
Trial registration: Trial registration: EudraCT 2012-000451-13.
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Corticosteroids and calcineurin inhibitors (CNIs), such
as tacrolimus and cyclosporine, are the main ingredients
in immunosuppressive renal transplantation protocols
throughout the world. These drugs have recognized side
effects, such as nephrotoxicity, an increased incidence of
diabetes, cardiovascular morbidity and malignancy. New
immunosuppressive drugs, such as mycophenolate mo-
fetil (MMF) and interleukin-2 receptor (IL2-R) anti-
bodies now make it possible to reduce, withdraw or
avoid corticosteroids or CNIs in many protocols [1].
Steroid-free protocols can now be used safely, providing
that a standard trough level of tacrolimus is achieved
and combined with MMF and IL2-R antibodies [2].
Doses of CNIs can also be reduced safely, as recently
shown in the large Symphony trial, in which the best
graft function was achieved in the study arm that used
low-dose tacrolimus [3]. However, as in most other
CNI-minimization protocols, corticosteroids were not
discontinued.
New onset of diabetes after transplantation (NODAT)
is associated with increased graft failure and mortality
due to cardiovascular events [4]. Long-term patient
survival is lower for patients with diabetes mellitus or
NODAT when compared with non-diabetic patients [5].
The incidence of NODAT is variously described as
reaching from 14% ten weeks after renal transplanta-
tion [6] to 37% one year after transplantation [7], and
NODAT has been a constant challenge in tacrolimus-
based immunosuppression since the drug was first
introduced. The incidence of NODAT has decreased as
tacrolimus doses have been reduced; but the incidence
still seems to be higher than for cyclosporine-based
regimens. The DIRECT study showed that the risk of
NODAT or impaired fasting glucose is common in CNI-
based regimens but is significantly lower with cyclosporine
than with tacrolimus in the first 6 months post-transplant
[8]. This is one reason cited by transplantation physicians
as to why they use cyclosporine rather than tacrolimus
with post-transplant patients perceived to be at risk of dia-
betes. As tacrolimus is a staple drug in modern immuno-
suppression [3], efforts to reduce NODAT rates have
focused on steroid withdrawal. As corticosteroids induce
insulin resistance, minimization is also likely to reduce
NODAT.
The CARMEN study group reported a significant re-
duction of NODAT (0.4%) in a steroid-free arm when
compared with a 5.4% rate for NODAT in a control arm
[2]. The steroid-free arm used daclizumab, tacrolimus
and MMF, while the control arm used tacrolimus, MMF
and steroids, without IL2-R antibody induction. In con-
trast, other studies have proposed that basiliximab, also
an IL2-R antibody, impaired glucose homeostasis and
was associated with an increased risk of NODAT [9,10].Antithymocyte globulin (ATG) has long been used as
a potent induction agent in organ transplantation. It has
been used in steroid-free [11,12] and CNI-minimization
protocols [13]. To better reduce side effects and toxicity,
the optimal immunosuppressive protocol would include
both avoidance of corticosteroids and minimization of
CNIs. No such protocols have appeared in the literature
or been otherwise described. A future protocol, designed
to avoid rejections due to inadequate immunosuppres-
sion will need to replace corticosteroids or CNIs by
increasing or optimizing other immunosuppressive strat-
egies. We believe that the use of ATG induction, instead
of IL2-R antibodies, along with the use of therapeutic drug
monitoring of MMF, would fit into such a protocol.
The proposed study aims at addressing both the diabe-
togenic side effect of CNIs and corticosteroids as well as
the cardiovascular side effects of corticosteroids in an
avoidance protocol.
Methods/Design
This is a prospective, multi-centre, controlled, random-
ized, parallel group, open-label study of participants who
are enrolled in kidney transplant programmes. The study
is comparing a steroid-free immunosuppressive protocol
based on low-dose tacrolimus and MMF maintenance
therapy together with ATG induction (study arm A) with
a conventional immunosuppressive protocol based on
low-dose tacrolimus and MMF and steroids together
with IL2-R induction (study arm B). The study design is
illustrated in Figure 1.
Prior to transplantation, a representative group of 222
de-novo kidney transplant recipients will be randomized
to either of the two study groups (111 in each group)
after signing an informed consent agreement. Assign-
ment of subjects to treatment groups will be stratified by
donor status (living versus deceased) and by centre.
Enrolment will continue until the required sample size
has been randomized. An enrolment time of 36 months
is expected.
The study includes persons above 18 years of age who
are receiving a first or second single kidney transplant
from a deceased or living donor and who are considered
able to benefit from a standard immunosuppressive
protocol. The study participants are able to give written
informed consent and each individual will need to agree
to participate in the study for 24 months.
Patients will be excluded from participation if they: (1)
already have a diagnosis of diabetes mellitus or have a
plasma glucose level of >11.1 mmol/l at admission; (2)
are receiving steroids at the time of transplantation; or
(3) are likely to need steroids after transplantation.
Recipients of multiorgan transplants, those previously
transplanted with any other organ than a kidney, or pro-
spective study participants with a complement dependent
Figure 1 Treatment and follow-up schedule in the SAILOR-study. ATG, antithymocyte globulin; AUC, area under the plasma concentration
time curve; IL2-R, interleukin-2 receptor; mGFR, measured glomerular filtration rate; MMF, mycophenolate mofetil; oGTT, oral glucose tolerance
test; Tx, transplant.
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recent tests are also excluded from the study. If the
responsible investigator considers the study candidate,
for any other reason, to be at a high risk of rejection
(which requires enhanced immunosuppression) then
the candidate will be excluded. Patients receiving a
renal transplant from a human leucocyte antigen (HLA)
identical sibling and patients who are recipients of ABO-
incompatible kidney transplants will also be excluded
from the study.
Objectives and endpoints
The primary objective of the study is to assess the
cumulative incidence of NODAT in the two study arms
12 months after transplantation. The NODAT diagnosis
being used is adapted from the American Diabetes Asso-
ciation criteria for type-2 diabetes [14]. The diagnosis
endpoint is measured as the cumulative incidence of:
 Fasting plasma glucose between 2 and 7.0 mmol/l,
30 consecutive days or more apart;
 2-hour plasma glucose ≥11.1 mmol/l in the oral
glucose tolerance test, 30 days or more apart;
 Use of oral hypoglycaemic agents for 30 consecutive
days or more;
 Insulin treatment for 30 consecutive days or more.
The oral glucose tolerance test will be administered
after 3 and 12 months. If either of the two oral glucose
tolerance tests is pathological, the reading will be con-
firmed by being repeated after 30 ± 7 days.
Secondary objective measures include other NODAT
time points and any use of antidiabetic medication. The
composite measure of freedom from acute rejection,graft survival and patient survival will be evaluated after
12 and 24 months. The incidence of antibody-mediated
rejection using the Banff 2009 classification [15] and of
donor-specific HLA antibodies will be analyzed after 3
and 12 months. Renal function will be evaluated by mea-
sured glomerular filtration rate mGFR and by Iohexol or
Cr-EDTA clearance at 12 and 24 months. The incidence
of chronic changes will be analyzed by protocol biopsies
at 12 months, using the Banff 2009 classification system.
The incidence of hypertension, number and type of
antihypertensive drugs and of lipid-lowering drugs will
be evaluated at different time points.Sample size calculation
In two recent phase 3 studies with tacrolimus, steroids
and MMF [7], the proposed definition of NODAT gave
an incidence rate of 36%. It is reasonable to estimate
that a steroid avoidance regimen can reduce the inci-
dence of NODAT to half of that rate. A changed induc-
tion regimen (Thymoglobulin rather than Simulect) is
expected to reduce the number of rejections. As de-
scribed earlier, the frequency of rejections has a positive
correlation with the incidence of NODAT.
We predict that the percentage of subjects who reach
the endpoint of NODAT after 12 months will be 18% in
the study group arm and 36% in the control group arm.
Based on this assumption, 222 subjects are required
for randomization to the two treatment groups in a 1:1
ratio (steroid-free: steroids) to achieve 80% power for
the superiority comparison (Fisher’s exact test) on the
intention-to-treat population of the primary endpoint
between the two treatment groups, with a two-sided
type I error of 5% and allowing for a 5% drop-out rate.
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The study participants will be randomized before trans-
plantation to one of the two following treatment arms
using a 1:1 relation from an internet-based system.
Study arm A: the steroid-free low-tacrolimus study
arm will receive Thymoglobulin® induction (2.5 mg/kg,
pre-or peri-operatively on day 0 and 2.5 mg/kg on day
1) and maintenance therapy of Advagraf® with an initial
preoperative dose of 0.1 mg/kg followed by 0.2 mg/(kg.
day) orally in one dose (concentration: 5 to 10 ng/ml;
after 3 months, 4 to 7 ng/ml); and MMF 1gx2 started
preoperatively, controlled by a single AUC (area under
the plasma concentration time curve) measurement, on
day 10 ± 5 days, with a target AUC of between 40 and 60
(mg.h)/l). To diminish ATG side effects, 250 mg methyl-
prednisolone will be given before ATG infusion on day 0
and 50 mg will be given before ATG infusion on day 1.
Study arm B: the standard low- tacrolimus study arm
protocol consists of Simulect® induction 20 mg intraven-
ously (day 0 and day 4) and maintenance immunosup-
pression with an initial preoperative dose of 0.1 mg/kg
followed by Advagraf® 0.2 mg/(kg.day) orally in one dose
(concentration: 5 to 10 ng/ml) and after 3 months (4 to
7 ng/ml). MMF 1gx2 is started preoperatively (controlled
by a single AUC measurement, on day 10 ± 5 days, with
a target AUC between 40 and 60 (mg.h)/l) and steroids
are added according to hospital practice, but not less
than 5 mg prednisolone daily after 6 months.
Trial organization
Called the SAILOR-study, this is an investigator-initiated
trial. Preliminary investigator meetings were organized
by Sahlgrenska University Hospital, the sponsor of the
study. Two Swedish transplant centres (Gothenburg,
Malmö) and one Danish centre (Aarhus) are participat-
ing in the study.
Study drugs will be purchased by the participating
hospitals. The investigation medicinal products will be
exempt from the EU Clinical Trials Directive as they will
be used within the terms of their marketing authorization.
All treatments will be on an open-label basis.
Before recruitment commenced, the sponsor visited all
sites to train relevant staff in the study procedures. The
sponsor will closely monitor recruitment rates and the
completeness of follow-up data. Sites will be monitored
during recruitment and follow-up through a combin-
ation of on-site visits and central statistical monitoring.
A data monitoring committee (DMC) will be ap-
pointed. An independent group, outside the sponsor and
steering group, will have this responsibility. The DMC
will consist of one or two physicians and one statistician;
none will have any other involvement with the study.
For efficacy, the DMC should use O’Brian-Fleming group
sequential boundaries. The DMC should also look forsafety and conditional power when giving advice regarding
continuation of the study. The DMC should start to look
at the data after 40% of the subjects have completed the
study.
The work of the DMC will be defined in a DMC char-
ter. The sponsor and DMC members, before their first
look at the data, should sign off this document when
40% of the subjects have completed the study.
The Regional Ethical Review Board in Sweden and
Denmark have approved the study. To protect partici-
pants, the study was designed to comply with the World
Medical Association’s current Declaration of Helsinki on
ethical principles of human experimentation.
The most relevant safety parameters assessed within
this study are incidence of diabetes mellitus, acute rejec-
tion, renal function, loss of graft, incidence of cardiovascu-
lar complications and events or incidence of malignancy.
Data on adverse events outside these topics will not be
collected.
Adverse events are recorded in the study’s case report
form. Serious adverse events are recorded in the case
report form, on a serious adverse events worksheet and
in the participant’s separate medical record.
The Transplant Institute, Gothenburg will be respon-
sible for all statistical programming and analysis, as well
as statistical quality control and validation of program-
ming and statistical analysis. The responsible biostatisti-
cian will coordinate the statistical analysis.
A detailed description of all the statistical analyses of
all efficacy and safety variables together with an over-
view of tables and figures will be given in a separate
statistical analysis plan. The plan will be finalized before
the database of the study is locked. Any deviations from
the plan will be justified in the clinical study report.
Discussion
This controlled study was designed to evaluate whether
a steroid-free, low-dose CNI protocol based on tacro-
limus, induction with a high-bolus dose of ATG and
therapeutic drug monitored MMF, may be used without
reduction in efficacy or safety and with side effects mini-
mized. The protocol is to be compared with a low-dose
CNI (tacrolimus) protocol with steroids and IL2-R in-
hibitor for induction.
Calcineurin inhibitors lower insulin secretion while ste-
roids contribute to insulin resistance. The β cell toxic ef-
fect when tacrolimus is used is, however, dose-dependent
and reversible [16]. If the tacrolimus concentration is kept
low, the risk for diabetes can be minimized [17]. The dif-
ference between tacrolimus and cyclosporine in lowering
insulin secretion has been shown to be present only very
early after transplantation, but not later on [18]. The Sym-
phony study sub-analysis describes no significant differ-
ence in fasting glucose between low-tacrolimus protocol
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trial, which used a cyclosporine-based regimen, the de-
novo use of antihyperglycemic medication was reduced
from 14.7% to 4.5% when steroids were avoided [20].
While diabetogenic effects of steroids and CNIs are well
documented, the role of IL2-R inhibitors in impairment of
glucose homeostasis have been discussed, but the results
are controversial [9,10].
The incidence of NODAT is dependent on how it is
defined. Using the American Diabetes Association defin-
ition of NODAT, we are expecting rates above 30% in
the steroid arm. We have not included HbA1c in diag-
nostic endpoints for NODAT, as it could be affected in
early transplant period by anemia, uremia and erythro-
poietin usage [21].
With early steroid withdrawal, one retrospective study
describes less rejection with ATG induction when com-
pared with IL2-R antibody blocker use [12]. Usually, the
drug is administered for 7 to 10 days after transplantation.
There is, however, clinical [22] as well as experimental
[23,24] evidence that suggests that a single high-bolus
dose of ATG given just before transplantation has a simi-
lar effect; a dose might even have tolerogenic properties.
In a large single-centre cohort, post-transplant diabetes
was significantly reduced when steroid-free immunosup-
pression was given and the frequency in the steroid-free
group was only 1% after 1 year [25].
Dosing of MMF may be optimized by increasing the
initial dose [26], and by the use of therapeutic drug
monitoring by estimated AUC measurements [27]. Opti-
mized usage of MMF can also reduce the risk of rejec-
tion in a steroid avoidance regimen.
In the experimental arm, participants will receive a
more powerful induction treatment (Thymoglobulin);
however, they will not receive steroids. We do not ex-
pect the experimental arm to be less effective in pre-
venting rejection and we expect that the steroid-free
regimen will reduce the rate of diabetes.
Study patients will undergo a biopsy after 1 year. Biop-
sies are frequently performed, but not on all patients out-
side a study. The risk for bleeding after biopsy is low but
sometimes a short period of haematuria is observed. Evi-
dence is increasing that surveillance biopsies not only give
information on acute rejection and chronicle changes but
also add other important information for the care of the
individual being treated [28,29]. An evaluation of implant-
ation biopsies will help to distinguish donor-related
changes from recipient-related processes.
Study participants will also undergo an oral glucose
tolerance test, which is not associated with any side
effects, other than the discomfort of drinking a strongly
sweet fluid.
If this study confirms the conceptual expectations,
namely a decreased incidence of NODAT, the steroid-free study protocol could be implemented among all study
participants. The regimen could be especially beneficial
among those with a high risk of diabetes mellitus or
significant cardiovascular complications and among those
with obesity, psychiatric conditions or skeletal deminera-
lization. Implementation, of course, has to be balanced
with a theoretically higher risk of rejection; the mainte-
nance therapy is limited to two drugs and could be con-
sidered weaker than the conventional triple regime. A
stronger induction therapy, with potential tolerance-
induced effect, is used to compensate for the lessened
maintenance immunosuppression. Signs of early acute
rejection will not be the only function monitored; chronic
changes, low-grade humoral rejection in protocol biopsies
at 1 year and any development of donor-specific HLA
antibodies will also be closely observed, to detect any sign
of long-term under-immunosuppression. The current
study has a two-year follow-up period and, therefore, can-
not give answers concerning long-term patient and graft
survival. We will consider extending the follow-up period
to 5 years if the outcome is as expected.
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